On this page
Evidence dossier
The report behind the claim
The authors reported preventive and later-treatment effects on the experimental pulmonary-hypertension syndrome. One toxin model does not establish treatment of the many forms of human pulmonary hypertension.
Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal.
- Design
- Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
- Participants or model
- Rats after a lung vascular injury caused by monocrotaline
- Endpoint
- Pulmonary pressure-related, heart and lung findings
- Finding on record
- The authors reported preventive and later-treatment effects on the experimental pulmonary-hypertension syndrome.
- Limits of inference
- One toxin model does not establish treatment of the many forms of human pulmonary hypertension.
The experiment in view
The study used rats after a lung vascular injury caused by monocrotaline. Its principal measures were pulmonary pressure-related, heart and lung findings. The authors reported preventive and later-treatment effects on the experimental pulmonary-hypertension syndrome.
Reading the result closely
The intervention timing distinguishes prevention from treatment after disease features appear. Combining those groups into one claim would conceal different questions. A human program would also have to address exercise capacity, symptoms, right-heart outcomes and interaction with established therapy.
The boundary of the finding
One toxin model does not establish treatment of the many forms of human pulmonary hypertension.
Related evidence, kept separate
BPC-157 in a severe potassium-chloride rat challenge examines eCG, electrolyte-related signs, survival and membrane potential. Here, the measured endpoint was pulmonary pressure-related, heart and lung findings. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the What changes when a BPC-157 paper becomes a sales claim? appraisal.
On the record
The documents supporting this report.